Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Blume-Jensen Peter received 252,801 Acrivon Therapeutics, Inc. shares as an award (Form 4)
Traded May 18, 2026 · Filed May 20, 2026
On May 18, 2026, Blume-Jensen Peter (Director, President and CEO) received 252,801 Acrivon Therapeutics, Inc. shares as an award, leaving 386,343 shares. Filed May 20, 2026 (Form 4).
- Awarded
- 252,801 shares
- Holding after
- 386,343 shares (held indirectly)
- Trading plan
- No
- Role
- Director, President and CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| May 18, 2026 | Common Stock | Award | 180,095 | 2,259,046 | Direct | |
| May 18, 2026 | Common Stock | Award | 72,706 | 386,343 | Indirect |
Source
Related
- Acrivon Therapeutics, Inc.
- Blume-Jensen Peter
- Acrivon Therapeutics, Inc. shareholders
- Form 4 · Blume-Jensen Peter · Aug 27, 2026
- Form 4 · Blume-Jensen Peter · May 18, 2026
- Form 4 · Miller Mary · Oct 7, 2026
- Form 4 · Levin Michaela · Sep 2, 2026
- Form 4 · Peterson Katharine · Aug 20, 2026
- Form 4 · Miller Mary · Aug 20, 2026
- Form 4 · Gamelin Erick · Aug 20, 2026